Arrowhead ResearchARWR
ARWR
About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Employees: 525
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
17% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $10.1M
3.13% more ownership
Funds ownership: 77.11% [Q3] → 80.24% (+3.13%) [Q4]
7% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 42
5% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 86
1% more capital invested
Capital invested by funds: $1.85B [Q3] → $1.87B (+$19.8M) [Q4]
0% more funds holding
Funds holding: 269 [Q3] → 269 (+0) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
238%
upside
Avg. target
$55
389%
upside
High target
$80
612%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Mayank Mamtani 9% 1-year accuracy 2 / 22 met price target | 238%upside $38 | Buy Reiterated | 14 Feb 2025 |
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target | 612%upside $80 | Buy Reiterated | 12 Feb 2025 |
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target | 274%upside $42 | Outperform Reiterated | 11 Feb 2025 |
Chardan Capital Keay Nakae 13% 1-year accuracy 9 / 72 met price target | 434%upside $60 | Buy Maintained | 11 Feb 2025 |
Financial journalist opinion
Based on 3 articles about ARWR published over the past 30 days
Neutral
Business Wire
4 days ago
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. “Ken has been a valuable member of the Arrowhea.
Neutral
Business Wire
2 weeks ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company's Board of Directors approved “inducement” grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest.
Positive
Seeking Alpha
4 weeks ago
Arrowhead Pharmaceuticals Is Finally Arriving
Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR's strong financial position is bolstered by a recent deal with Sarepta, extending its cash runway into 2028.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025. Select Phase 1/2 Study Results Patients with IgA nephrop.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass comp.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS). FCS is an ultra-rare genetic disorder that signi.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada. ARO-ALK7 is the first RNAi-based therapy to directly targe.
Positive
Seeking Alpha
1 month ago
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.
Positive
Market Watch
1 month ago
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.
Neutral
Seeking Alpha
2 months ago
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B.
Charts implemented using Lightweight Charts™